BP
VIR icon

Ballentine Partners’s Vir Biotechnology VIR Stock Holding History

Ballentine Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,743
Closed -$59.2K – 1068
2025
Q2 		$59.2K Buy
11,743
+968
+9% +$5.19K ﹤0.01% 959
2025
Q1 		$69.8K Sell
10,775
-159
-1% -$1.41K ﹤0.01% 871
2024
Q4 		$80.3K Sell
10,934
-442
-4% -$3.49K ﹤0.01% 853
2024
Q3 		$85.2K Sell
11,376
-1,143
-9% -$9.93K ﹤0.01% 812
2024
Q2 		$111K Sell
12,519
-1,185
-9% -$11.4K ﹤0.01% 722
2024
Q1 		$139K Buy
13,704
+1,160
+9% +$11.8K ﹤0.01% 698
2023
Q4 		$126K Buy
12,544
+1,915
+18% +$17.5K ﹤0.01% 651
2023
Q3 		$99.6K Buy
+10,629
New +$152K ﹤0.01% 578

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return